Rich-Vicks says McNeil, Upjohn should not be granted new judgment or trial.
This article was originally published in The Tan Sheet
RICH-VICKS SAYS McNEIL's "UNCLEAN HANDS" UNDERMINE ROYALTY ARGUMENT that the company be allowed to recoup its investment in developing a 200 mg ibuprofen/30 mg pseudoephedrine combination product before having to pay Rich-Vicks a 7% royalty. The royalty was awarded when a jury found that Motrin IB Sinus and Sine-Aid IB were infringing Rich-Vicks' patent for the 200 mg ibuprofen/30 mg pseudoephedrine combination ("The Tan Sheet" May 22, p. 1). Rich-Vicks, a unit of Procter & Gamble, made the allegation of "unclean hands" in briefs filed with the Delaware federal court on June 8. The defendants submitted their final round of reply briefs on June 15.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC